Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Am J Surg Pathol. 2014 Apr;38(4):448–460. doi: 10.1097/PAS.0000000000000134

Figure 5. Cumulative incidence of recurrence (CIR) by lepidic predominant subtypes.

Figure 5

Patients with AIS and MIA (n=36) experienced no recurrences (5-year CIR, 0%). Patients with lepidic predominant invasive adenocarcinoma had a lower risk of recurrence (n=103, 5-year CIR, 8%) than patients with non-lepidic predominant adenocarcinoma (n=899; 5-year CIR, 19%).